Company intelligence / Profile preview

Charsire Biotechnology

Tainan City/Xinshi District, Tainan City/Tainan Province, Taiwanfda.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Charsire’s lead drug BAC has completed Phase II clinical trials with promising results—79% of patients maintained or improved at week 4 without any dementia medication; this increased to 86% by week 12. No side effects were reported. The company claims BAC improves brain blood circulation, reduces inflammation, and promotes nerve cell regeneration. Phase III trials are ongoing in the US for both Alzheimer’s disease and vascular dementia

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecules (notably botanical and phytotherapy-based drugs)
Industry: Biotech

Drug pipeline

3 assets

CSTC1

2 more assets in the full pipeline.

Request access →

Partnerships

Seeking partners for global expansion but no major partnerships disclosed yet

Beyond the preview

Go deeper on Charsire Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Charsire Biotechnology.

Explore the full profile